Literature DB >> 30098016

Infectious events and associated risk factors in mycosis fungoides/Sézary syndrome: a retrospective cohort study.

R Blaizot1,2, E Ouattara3,4,5,6, A Fauconneau2, M Beylot-Barry2,7, A Pham-Ledard2,7.   

Abstract

BACKGROUND: Infections are one of the major causes of death in patients with advanced-stage mycosis fungoides (MF) or Sézary syndrome (SS). However, few recent data are available on the characteristics and risk factors of these infectious events.
OBJECTIVES: To describe infectious events occurring in a cohort of patients with MF/SS, and to identify associated clinical and biological risk factors.
METHODS: A retrospective cohort study was performed to investigate infectious events and associated factors in patients diagnosed with MF (stage IB and beyond) or SS followed from May 2011 to May 2016 at the University Hospital of Bordeaux, France.
RESULTS: Seventy-one patients with complete follow-up were included. Eighty infectious events were recorded in 40 patients, including 28 skin and soft tissue infections and 25 cases of pneumonia. Opportunistic infections, which are usually associated with depleted cell-mediated immunity, were scarce (9%). In multivariate analysis, cardiac, renal or lung comorbidities [odds ratio (OR) 7·2, 95% confidence interval (CI) 3·3-15·9; P = 0·002], SS (OR 8·8, 95% CI 7·7-10·2; P = 0·037) and lymphocyte count < 0·5 × 109 cells L-1 (OR 6·4, 95% CI 1·5-27·4; P = 0·004) were significantly associated with a higher risk of infection.
CONCLUSIONS: Opportunistic germs were rarely recorded, but their incidence was probably prevented by adequate prophylaxis (ongoing in 28% of patients). As in patients living with AIDS, pneumonias were frequent. On the other hand, bacterial cutaneous infections represent a specific pattern in patients with MF/SS. Patients with chronic organ failure, lymphocytopenia and SS should be considered as being at high risk for infectious events. Pneumococcal vaccination should be systematically recommended, and prophylaxis with co-trimoxazole and valaciclovir when the CD4 count is < 0·2 × 109 cells L-1 .
© 2018 British Association of Dermatologists.

Entities:  

Mesh:

Year:  2018        PMID: 30098016     DOI: 10.1111/bjd.17073

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  12 in total

1.  Risk of bacteremia in patients with cutaneous T-cell lymphoma (CTCL).

Authors:  Pamela B Allen; Jeffrey Switchenko; Amy Ayers; Esther Kim; Mary Jo Lechowicz
Journal:  Leuk Lymphoma       Date:  2020-06-19

2.  Antibiotics inhibit tumor and disease activity in cutaneous T-cell lymphoma.

Authors:  Lise M Lindahl; Andreas Willerslev-Olsen; Lise M R Gjerdrum; Pia R Nielsen; Edda Blümel; Anne H Rittig; Pamela Celis; Bjorn Herpers; Jürgen C Becker; Birgitte Stausbøl-Grøn; Mariusz A Wasik; Maria Gluud; Simon Fredholm; Terkild B Buus; Claus Johansen; Claudia Nastasi; Lukas Peiffer; Linda Kubat; Michael Bzorek; Jens O Eriksen; Thorbjørn Krejsgaard; Charlotte M Bonefeld; Carsten Geisler; Tomas Mustelin; Erik Langhoff; Michael Givskov; Anders Woetmann; Mogens Kilian; Thomas Litman; Lars Iversen; Niels Odum
Journal:  Blood       Date:  2019-07-22       Impact factor: 22.113

3.  Single-Cell RNA Sequencing Unveils the Clonal and Transcriptional Landscape of Cutaneous T-Cell Lymphomas.

Authors:  Alyxzandria M Gaydosik; Connor J Stonesifer; Alexandra E Khaleel; Larisa J Geskin; Patrizia Fuschiotti
Journal:  Clin Cancer Res       Date:  2022-06-13       Impact factor: 13.801

4.  Staphylococcus aureus enterotoxins induce FOXP3 in neoplastic T cells in Sézary syndrome.

Authors:  Andreas Willerslev-Olsen; Terkild B Buus; Claudia Nastasi; Edda Blümel; Maria Gluud; Charlotte M Bonefeld; Carsten Geisler; Lise M Lindahl; Maarten Vermeer; Mariusz A Wasik; Lars Iversen; Jürgen C Becker; Mads Hald Andersen; Lise M R Gjerdrum; Ivan V Litvinov; Thomas Litman; Thorbjørn Krejsgaard; Anders Woetmann; Niels Ødum
Journal:  Blood Cancer J       Date:  2020-05-14       Impact factor: 11.037

5.  Staphylococcal alpha-toxin tilts the balance between malignant and non-malignant CD4+ T cells in cutaneous T-cell lymphoma.

Authors:  Edda Blümel; Andreas Willerslev-Olsen; Maria Gluud; Lise M Lindahl; Simon Fredholm; Claudia Nastasi; Thorbjørn Krejsgaard; Bas G J Surewaard; Sergei B Koralov; Tengpeng Hu; Jenny L Persson; Charlotte Menné Bonefeld; Carsten Geisler; Lars Iversen; Jürgen C Becker; Mads Hald Andersen; Anders Woetmann; Terkild Brink Buus; Niels Ødum
Journal:  Oncoimmunology       Date:  2019-07-17       Impact factor: 8.110

6.  Expression and function of Kv1.3 channel in malignant T cells in Sézary syndrome.

Authors:  Tengpeng Hu; Terkild Brink Buus; Thorbjørn Krejsgaard; Anneline Nansen; Betina Kerstin Lundholt; Pieter Spee; Simon Fredholm; David Leander Petersen; Edda Blümel; Maria Gluud; Madalena N Monteiro; Andreas Willerslev-Olsen; Mads Hald Andersen; Per Thor Straten; Özcan Met; Veronica Stolearenco; Hanne Fogh; Robert Gniadecki; Claudia Nastasi; Thomas Litman; Anders Woetmann; Lise Mette Rahbek Gjerdrum; Niels Ødum
Journal:  Oncotarget       Date:  2019-08-06

7.  Functional Depletion of HSP72 by siRNA and Quercetin Enhances Vorinostat-Induced Apoptosis in an HSP72-Overexpressing Cutaneous T-Cell Lymphoma Cell Line, Hut78.

Authors:  Kazuyasu Fujii; Masashi Idogawa; Norihiro Suzuki; Keiji Iwatsuki; Takuro Kanekura
Journal:  Int J Mol Sci       Date:  2021-10-19       Impact factor: 5.923

8.  Alitretinoin in the treatment of cutaneous T-cell lymphoma.

Authors:  Till Kaemmerer; Pia-Charlotte Stadler; Leonie Helene Frommherz; Anne Guertler; Lars Einar French; Markus Reinholz
Journal:  Cancer Med       Date:  2021-08-25       Impact factor: 4.452

9.  COVID-19 infection in patients with Sézary syndrome: Report of two cases.

Authors:  Yung Gonzaga; Mayne Batista Fontes Santos; Marcia Matos Silva; Márcio Nucci
Journal:  Dermatol Ther       Date:  2020-08-13       Impact factor: 3.858

10.  Primary cutaneous lymphoma and risk for severe COVID-19: a prospective study of 48 cases in Morocco.

Authors:  H Kerrouch; M Khalidi; R Frikh; N Hjira; M Boui
Journal:  J Eur Acad Dermatol Venereol       Date:  2022-03-17       Impact factor: 9.228

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.